New treatment option for older patients with blood cancer
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
Visitor information – Everything you need to know about visiting our sites.
Our group explores novel therapeutic approaches for multiple myeloma (MM) in preclinical and clinical studies.
We are evaluating the activity and mechanism of action of epigenetic modifying agents as well as undertaking preclinical development of both a novel anti-MM monoclonal antibody, Mab, and the orally bioavailable-catenin inhibitor BC2059.
We secured funding from the Victorian Cancer Agency, International Myeloma Foundation and pharmaceutical industry partners and activated the Myeloma and Related Diseases Registry aligned national biobanking initiative, the Myeloma 1000 Project.
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
The Alfred and Monash University are set to establish Australia’s first dedicated blood cancer research centre, thanks to a $1.2 million grant from the Australian Cancer Research Foundation (ACRF).